SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending following the announcement of a new CEO from Shopify and the return of co-founders to the board, sparking optimism about the company's future and driving significant after-hours gains. The community is rallying against short-sellers, anticipating a potential short squeeze, and some are drawing comparisons to past high-momentum stocks. Discussions also involve the potential impact of interest rate cuts and overall market conditions on the real estate sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid discussion and outrage following the death of Charlie Kirk, founder of Turning Point USA.  Community members are sharing their perspectives on Kirk's legacy, gun control, and political violence.  The incident has sparked heated debate and division, with some users calling for unity and others expressing strong opinions on the political implications.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its recent airdrop and the establishment of a new liquidity pool paired with USDC, fostering price stability. The community is excited about these developments and anticipates further growth, emphasizing the project's strong community and active development team. Many believe $BROKE has the potential to disrupt the internet.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending amid community excitement and speculation around its potential, partnerships, and upcoming earnings report in early October. Some investors are drawing comparisons to other AI companies and expressing long-term bullish sentiment, while others discuss potential dilution and short-term trading strategies. A special meeting scheduled for late September 2025 is also generating buzz.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions of its potential for further gains, driven by its fast and cheap transactions. The community is actively discussing staking opportunities, potential new highs, and corporate adoption, along with comparisons to other major cryptocurrencies like Ethereum and Bitcoin. Some are also excited about the launch of new projects within the Solana ecosystem.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential breakouts and retests of key resistance levels. The focus is on Pyth's role in the Real World Asset (RWA) space and its potential impact on the market data industry. Some community members are speculating on adoption by larger entities and future price targets.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to growing excitement around potential new deals with major hyperscalers in the AI sector, especially after NBIS announced a significant agreement with Microsoft. The community is actively discussing upcoming catalysts like a key vote and the launch of a leveraged ETF. Some anticipate a potential short squeeze amid the AI infrastructure boom.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu ($SHI.X) is trending as traders discuss its bullish chart patterns and potential for a breakout, with some believing a significant rally is imminent. The community highlights the strong tokenomics and growing awareness of the project, anticipating a community-driven surge. Despite some skepticism, many see long-term potential, citing strong community engagement and a possible shift in momentum.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending due to a convertible note offering, sparking debate about the company's financial strategy and potential acquisitions. The community is split between those who view the offering as a positive step towards expansion and those who are concerned about dilution and management's communication. Discussions also involve potential customers and the competitive landscape of battery technology.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys ($SNPS) is trending due to a significant earnings miss and slashed FY25 outlook, leading to a sharp stock decline and sparking debates about its valuation and future prospects. Community discussions revolve around potential bottom levels, oversold conditions, and whether the drop presents a buying opportunity or a value trap, especially considering the company's exposure to China and the AI sector. Some traders are eyeing a potential bounce, while others are bracing for further downside, with analysts weighing in with revised price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cyclacel Pharmaceuticals, Inc. (CYCC) has been in a downward spiral in 2025, with its stock plunging over 94% year-to-date and more than 76% even after it regained Nasdaq compliance earlier this month.The clinical-stage biotech firm, based in Berkeley Heights, New Jersey, focuses on cancer treatments targeting cell cycle, transcriptional regulation, epigenetics, and mitosis. However, its lead candidates—fadraciclib (a CDK2/9 inhibitor) and plogosertib (a PLK1 inhibitor)—have failed to inspire investor confidence.The trouble began in October 2024, when initial Phase 2 data from a trial of fadraciclib in solid tumors showed only two patients with stable disease among six efficacy-evaluable participants.Research firm Roth MKM called the results “not encouraging,” especially given the patients' favorable genetics, adding that Cyclacel required three or more patient responses to justify continued development.That triggered a sharp fall in <a href="https://stocktwits.com/symbol/CYCC">Cyclacel shares</a>. Struggling to stay afloat, the company then turned to investor David Lazar in January for a $3.1 million funding deal, which included leadership shuffling. Lazar was named interim CEO, replacing longtime chief Spiro Rombotis, and several board members stepped down.In March, Cyclacel raised another $1 million through a private placement of convertible preferred stock.&nbsp;Two months later, Cyclacel pivoted sharply, announcing plans to acquire Fitters Sdn. Bhd., a Malaysian firm focused on fire safety and waste-to-resource solutions. The deal, structured as a share exchange with FITTERS Diversified Bhd., will give the parent company nearly 20% of Cyclacel’s stock. Cyclacel shareholders will retain 80%, and the company said it would rebrand as Bio Green Med Solution, Inc., with a new ticker on the Nasdaq.The merger still requires shareholder approval and must close by Aug. 31.Retail sentiment for CYCC has turned increasingly ‘bearish’ over this period, accompanied by a fourfold jump in message volume over the past month.The company’s rebranding and Nasdaq compliance milestone have failed to stem the stock’s decline, indicating investor skepticism about the firm’s future direction.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Cyclacel Stock Tumbles Over 76% Since Regaining Nasdaq Compliance: What’s Ailing the Nanocap Biopharma Firm?

The company’s rebranding and leadership shuffle have failed to stem the stock’s decline, indicating investor skepticism about its future direction.

Equity

Sangamo Therapeutics, Inc. ($SGMO)Sangamo shares spiked over 30% by the mid-session with sentiment on Stocktwits continuing to remain ‘extremely bullish’ for a second day in running. This marks a turnaround from a week ago when the sentiment score was 35/100.&nbsp;As of 3:05 pm ET, pn Stocktwits the sentiment score was at 97/100. Message volume has improved from ‘normal’ a month ago to ‘extremely high’ this week.&nbsp;On Tuesday, Sangamo announced its successful interaction with the U.S. FDA that provided a clear regulatory pathway to the accelerated approval for ST-920, a wholly-owned gene therapy to treat Fabry disease.&nbsp;The drug regulator agreed in the interaction that the data from the ongoing Phase 1/2 STARR study&nbsp;can serve as the primary basis for approval under the Accelerated Approval Program.&nbsp;“I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated,” said Sandy Macrae, CEO of Sangamo.<figure class="image"><a href="https://stocktwits.com/symbol/SGMO"><img style="aspect-ratio:643/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/sgmo_sentiment_8fa3195ce2.png" alt="sgmo sentiment.png" width="643" height="147"></a><figcaption>&nbsp;SGMO sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The company said it plans to submit the Biologic License Application in 2025.Cyclacel Pharmaceuticals, Inc. ($CYCC)Nano-cap biotech Cyclacel also saw a surge in retail interest. The&nbsp;sentiment meter on Stocktwits&nbsp;was trending in the ‘extremely bullish’ territory, with a score of 96/100 as of 3:05 pm ET. This marked an improvement from the ‘bullish’ predisposition seen on Monday. Message volume has spiked significantly, with the corresponding score improving from 63/100 on Monday to 93/100.<figure class="image"><a href="https://stocktwits.com/symbol/CYCC"><img style="aspect-ratio:627/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/cycc_sentiment_58035ef869.png" alt="cycc-sentiment.png" width="627" height="138"></a><figcaption>CYCC sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The extremely positive stance of retail traders came ahead of the oncology-focused company’s presentation of the initial safety and efficacy data from&nbsp;12 patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent.&nbsp;The data is due to be presented between 6 am ET and1 pm ET on October 23, 2024 at the AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics to be held in Barcelona, Spain.GE Aerospace ($GE)GE Aerospace stock was plunging on Tuesday following the company’s third-quarter results, which showed revenue coming in slightly shy of estimates. The adjusted earnings from continuing operations, however, beat the consensus.Retail investors threw their weight behind the company, with the sentiment score on Stocktwits at 96/100 as of 3:05 pm ET, suggesting ‘extreme bullishness.’ The score is up from 79 a day ago. Message volume has been extremely high, with a score of 96/100, up from 72/100 on Monday.&nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/GE"><img style="aspect-ratio:667/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ge_sentiment_f01d6d0683.png" alt="ge-sentiment.png" width="667" height="137"></a><figcaption>GE sentiment and message volume October 22, 2024, as of 3:05 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>As of 3:05 pm ET, Sangamo was up 35.3% at $1.24, Cyclacel gained 12.55% to $1.49, while GE Aerospace fell 8.84% to $177.05.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/texas-instruments-stock-slips-ahead-of-earnings-retail-sentiment-turns-bullish-amid-rise-in-chatter/cJ2XQFWReS">Texas Instruments Stock Slips Ahead Of Earnings, Retail Sentiment Turns Bullish Amid Rise In Chatter</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon

These 3 stocks are riding on catalysts in Tuesday's session.

3 stocks outperforming the broader market Tuesday

A small-cap biotech and a far smaller nano-cap peer and GE Aerospace were among the stocks retail traders were the most bullish about on Tuesday.


Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Large Decline in Short Interest

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC  Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 26,600 shares, a drop of 35.9...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to "Hold" at StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a report issued on Tuesday morning.
A number of other brokerages...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Downgraded by StockNews.com

StockNews.com cut shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a hold rating to a sell rating in a research report report published on Monday morning. Other analysts have...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation Oral Plogosertib Preclinical Data Support Precision...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC  Free Report) from a sell rating to a hold rating in a research note released on Thursday morning. Several other...

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel...

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals Inc

Buying for a long-term investment

Buying for a short-term trade

Trading around the volatility

Avoiding it

$KLAR IPO day is upon us, how are you playing it?

Stocktwits

Klarna Group plc

 IPO day is upon us, how are you playing it?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	--	-$0.98	--	N/A
Q1 '25	--	$0.00	--	N/A
Q4 '24	-$69.60	-$5.28	92.41%	BEAT
Q3 '24	-$0.54	-$0.18	66.67%	BEAT
Q2 '24	-$1.43	-$0.72	49.83%	BEAT

CYCC
Cyclacel Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '25

Historical Earnings

Latest CYCC News

CYCC Cyclacel Pharmaceuticals Inc